During the trial, 1 patient with CP-A cirrhosis (4.2%, placebo) and 3 patients with CP-B cirrhosis (12.0%; n = 1 each per 2 mg BID, 3 mg BID, and placebo) discontinued trial medication: 2 due to an AE (CP-B, n = 1 each per 3 mg BID [delirium] and placebo [hematemesis, non-variceal]) and 2 due to withdrawal by participant (CP-A: n = 1, placebo; CP-B: n = 1, 3 mg BID). Here, CP is linked to congenital primary aphakia.